Solid Biosciences Revenue and Competitors

Boston, MA USA

Location

$366.3M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Solid Biosciences's estimated annual revenue is currently $10.5M per year.(i)
  • Solid Biosciences received $133.7M in venture funding in February 2018.
  • Solid Biosciences's estimated revenue per employee is $78,134
  • Solid Biosciences's total funding is $366.3M.
  • Solid Biosciences's current valuation is $155M. (January 2022)

Employee Data

  • Solid Biosciences has 134 Employees.(i)
  • Solid Biosciences grew their employee count by 10% last year.

Solid Biosciences's People

NameTitleEmail/Phone
1
CEO and PresidentReveal Email/Phone
2
SVPReveal Email/Phone
3
VP, Legal Corporate & IPReveal Email/Phone
4
VP Technical QA and QCReveal Email/Phone
5
VP, Head Clinical OperationsReveal Email/Phone
6
VP, Clinical OperationsReveal Email/Phone
7
VP ManufacturingReveal Email/Phone
8
SVP, Head Human Resources & Administrative OperationsReveal Email/Phone
9
VP, Portfolio and Program ManagementReveal Email/Phone
10
Head Bioanalytical SciencesReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$12.7M82-45%$107.3MN/A
#2
$0.2M1-50%N/AN/A
#3
$6.2M4021%N/AN/A
#4
$42.2M2184%$165MN/A
#5
$14.6M94-37%$312.8MN/A
#6
$0.3M2-67%N/AN/A
#7
$235M366-5%$340.9MN/A
#8
$56M289-7%$7.6MN/A
#9
$4.7M6136%N/AN/A
#10
$2M138%N/AN/A
Add Company

What Is Solid Biosciences?

Solid Biosciences (Solid) is a Cambridge, MA based biotech company singularly focused on developing treatments and cures for Duchenne muscular dystrophy (DMD). Solid combines sharp commercial focus with world-class science to advance promising therapies and is positioned to catalyze therapeutic development across all aspects of the disease. Condition-focused, our mandate is comprehensive; improving daily life for patients and attacking the roots of DMD.

keywords:Biotechnology,Healthcare,Pharmaceuticals

$366.3M

Total Funding

134

Number of Employees

$10.5M

Revenue (est)

10%

Employee Growth %

$155M

Valuation

N/A

Accelerator

Solid Biosciences News

2022-04-19 - Solid Biosciences Management to Host Call on April 27, 2022 to ...

Solid Biosciences is a life sciences company focused on advancing transformative treatments to improve the lives of patients living with...

2022-04-06 - Zacks: Analysts Expect Solid Biosciences Inc. (NASDAQ:SLDB) Will ...

Three analysts have issued estimates for Solid Biosciences' earnings, with the highest EPS estimate coming in at ($0.17) and the lowest estimate...

2022-03-30 - Is it Time to Dump Solid Biosciences Inc (SLDB) Stock After it Is Down 0.00% in a Week?

Solid Biosciences Inc (SLDB) stock is unchanged 0.00% over the past week and gets a Bearish rating from InvestorsObserver Sentiment...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$18.8M134-28%N/A
#2
$27.5M13513%N/A
#3
$15M136-9%N/A
#4
$17.8M137-8%$119.7M
#5
$45.2M137-13%N/A

Solid Biosciences Funding

DateAmountRoundLead InvestorsReference
2015-11-04$42.5MBerceptive Advisors, LLCArticle
2017-03-31$50.0MCRA Capital ManagementArticle
2018-02-01$133.7MUndisclosedJ.P. MorganArticle